Dr. Nathan Pennell received his Ph.D. in neuroscience in 1998 and his M.D. in 2002 from the University of Florida College of Medicine in Gainesville, FL. He then moved to Boston to do his internal medicine internship and residency training at Brigham & Women’s Hospital, and completed his medical oncology fellowship at the Dana Farber Cancer Institute, also in Boston. While there, he developed an expertise in lung cancer, mesothelioma, and thyroid cancer. He moved to the friendly midwest in 2008 to continue with this focus at the Taussig Cancer Institute at the Cleveland Clinic.
Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.
Dr. Alice Shaw joined GRACE to discuss controlling brain metastases in patients with molecular driven advanced non-small cell lung cancer.
Alice T. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. She received her A.B. in Biochemistry from Harvard and her M.D. and Ph.D. degrees from Harvard Medical School. She did her residency in Internal Medicine at Massachusetts General Hospital and completed a fellowship in Hematology/Oncology at Dana-Farber/Massachusetts General Hospital. She completed her postdoctoral work in the laboratory of Dr.
Karen Reckamp, MD, MS, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center (COHCCC). She received her medical degree from University of Chicago, and her master’s degree in Clinical Investigation from UCLA. She completed residency training in Internal Medicine at Barnes-Jewish Hospital and a Hematology/Oncology fellowship at the David Geffen School of Medicine at UCLA.
Matt Hiznay is a five-year survivor of metastatic, ALK-positive non-small cell lung cancer. He was born in Youngstown, Ohio, and grew up in the small town of Poland, Ohio. Matt graduated from Poland Seminary High School in 2006 and from John Carroll University in 2010 with a Bachelor of Science degree magna cum laude.
Janet Freeman-Daily is a writer, science geek, and lung cancer patient/activist. She received a diagnosis of advanced non-small cell lung cancer in May 2011 which became metastatic despite chemotherapy and radiation. After learning about genomic testing and precision medicine in online patient communities, she joined a clinical trial for ROS1-positive lung cancer and has had no evidence of disease for over four years.
John Cherol was diagnosed in January 2016 with Stage IV EGFR+ lung cancer at the age of 28. He started Gilotrif (afatinib) and acquired resistance after 14 months. Luckily a blood test showed he developed the t790m mutation and he started Tagrisso in April of this year. He’s also been treated for nine brain mets with Gamma Knife at the Cleveland Clinic.
Dr. Wakelee is an assistant professor of medicine at Stanford University in the Division of Oncology where she is the co-leader of the lung cancer disease management group. Her focus is in clinical research in lung cancer patients, and she has a particular interest in anti-angiogenesis agents. Dr. Wakelee is the principal investigator of the ongoing International Lung Cancer Intergroup Trial E1505 that is investigating the potential role of bevacizumab in addition to adjuvant chemotherapy for resected early-stage, non-small cell lung cancer.